What Is PUR4? Definition and What Research Reports

Definition

PUR4 — written pUR4 in most peptide publications, and also referred to as FUD ("functional upstream domain") — is a short bacterial-derived polypeptide that binds tightly to the amino-terminal region of fibronectin and prevents fibronectin from being assembled into insoluble fibrils in the extracellular matrix. In the literature the two names are frequently combined as "pUR4/FUD", as in a 2018 report describing a PEGylated version of the peptide as an inhibitor of fibronectin fibrillogenesis tested in a murine unilateral ureteral obstruction model of kidney disease (PMID 30356276). Confusingly, the same four characters in uppercase — PUR4 — are also a gene symbol in plant and fungal genetics, where they denote a purine-biosynthesis gene with no relationship to the fibronectin-binding peptide. This entry is definitional only.

What Class of Molecule It Is and Where It Comes From

pUR4/FUD is generally described as a recombinant polypeptide rather than a small synthetic peptide: it is a fibronectin-binding fragment originating from a streptococcal adhesin protein, expressed recombinantly and used experimentally as a molecular tool. Functionally it belongs to a small group of agents classified as fibronectin assembly inhibitors or fibronectin fibrillogenesis inhibitors. Its mechanism, as the name implies, is competitive interference with the fibronectin–fibronectin interactions required for matrix fibril formation, rather than enzymatic inhibition or receptor agonism.

Because native polypeptides of this size are cleared quickly, investigators have explored chemical modification of the molecule. One approach reported in the published record was PEGylation — the attachment of polyethylene glycol — with the PEGylated pUR4/FUD peptide described as an inhibitor of fibronectin fibrillogenesis in a study that tested it in a murine kidney disease model (PMID 30356276).

Two Different Things Called "PUR4"

Readers searching the term should note which literature they have landed in: a paper about "pur4 mutations" in a model plant is a genetics paper, not a peptide paper.

How the Term Is Used in Peptide Research

In peptide and matrix-biology papers, pUR4 is typically used as an experimental probe — a way to ask what happens to a cell, tissue or organ when fibronectin matrix assembly is blocked. Researchers apply it to cultured cells or administer it to animals and then measure downstream outcomes such as barrier function, integrin signalling, or the accumulation of fibrotic matrix. In that sense the term functions much like a reagent name in the methods section, and papers often pair it with the alternative label FUD so that the same molecule can be traced across the literature.

Two broad research threads appear in the verified literature: endothelial barrier and vascular permeability, and organ fibrosis. Both reflect the underlying biology that fibronectin matrix influences how cells adhere, signal through integrins, and deposit further matrix.

What the Published Literature Reports

Endothelial permeability and β1 integrin

A 2019 study published in the Journal of Biomedical Science examined pUR4 as a fibronectin inhibitor and reported that it attenuated tumour necrosis factor α–induced endothelial hyperpermeability by modulating β1 integrin activation (PMID 31096970). In that work the peptide was used to interrogate the link between fibronectin matrix, integrin signalling and endothelial barrier integrity under an inflammatory stimulus (PMID 31096970).

Fibrosis in a rodent kidney model

A 2018 PLoS One report described a PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis and reported decreased fibrosis in the murine unilateral ureteral obstruction model of kidney disease (PMID 30356276). Unilateral ureteral obstruction is a standard surgical rodent model used to generate rapid, reproducible kidney scarring, so the study was a model-system investigation rather than a clinical trial (PMID 30356276).

The gene literature

On the genetics side, a 2008 Plant Physiology paper reported that pur4 mutations were lethal to the male but not the female gametophyte and affected sporophyte development in Arabidopsis (PMID 18441219). A 2000 Russian-language Genetika paper addressed genetic control of purine biosynthesis in Pichia methanolica yeast and described the ADE5 (PUR4) gene as controlling 5'-phosphoribosylformylglycineamide synthetase (PMID 11190471). Neither paper concerns the fibronectin-binding peptide.

Safety and Adverse Events: What Studies Report

The verified literature summarised on this page consists of cell-culture and animal work and of plant and yeast genetics; none of these publications was a human clinical trial, and none is presented here as evidence about human safety. The 2019 endothelial work was a mechanistic investigation of TNF-α–induced hyperpermeability and β1 integrin activation (PMID 31096970), and the 2018 kidney work was conducted in a surgical mouse model of obstructive kidney injury (PMID 30356276). No dose, schedule, or route from these publications is reproduced on this page, because the outcomes they reported belong to those specific experimental systems. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any substance you encounter in the research literature.

Limits of the Evidence

• Preclinical only. The verified record here covers cultured cells, mice and non-animal model organisms. Findings in these systems do not automatically transfer to humans.
• Small evidence base. Only a handful of papers on the peptide are summarised here, and single studies — however carefully done — are not the same as a replicated body of work.
• Molecular-tool framing. In the sources cited, pUR4 was used as a means of blocking fibronectin assembly so that researchers could observe what changed; that is a different purpose from developing a therapeutic product.
• Naming ambiguity. Because the gene symbol PUR4 appears in unrelated plant and yeast literature (PMID 18441219), database searches on the bare term retrieve two disconnected bodies of work.

Related Terms

• FUD (functional upstream domain) — the alternative name for the same fibronectin-binding polypeptide, used interchangeably as "pUR4/FUD" (PMID 30356276).
• Fibronectin fibrillogenesis — the process of assembling soluble fibronectin into insoluble matrix fibrils, the step the peptide is described as inhibiting (PMID 30356276).
• β1 integrin — a cell-surface adhesion receptor whose activation was reported to be modulated in the 2019 endothelial permeability study (PMID 31096970).
• PEGylation — chemical attachment of polyethylene glycol, applied to the peptide in the 2018 kidney model report (PMID 30356276).

References

• Fibronectin inhibitor pUR4 attenuates tumor necrosis factor α-induced endothelial hyperpermeability by modulating β1 integrin activation (Journal of Biomedical Science, 2019)
• PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease (PLoS One, 2018)
• pur4 mutations are lethal to the male, but not the female, gametophyte and affect sporophyte development in Arabidopsis (Plant Physiology, 2008)
• [Genetic control of purine biosynthesis in Pichia methanolica yeast. The ADE5 (PUR4) gene, controlling 5'-phosphoribosylformyl glycineamide synthetase] (Genetika, 2000)